Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cantargia AB (publ) (CANTA.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
16.10+0.05 (+0.31%)
At close: 05:29PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.05
Open16.05
Bid16.05 x 0
Ask16.18 x 0
Day's Range15.67 - 16.18
52 Week Range14.80 - 59.60
Volume123,674
Avg. Volume521,841
Market Cap1.613B
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-3.23
Earnings DateFeb 24, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.50
  • PR Newswire

    Cantargia reports third party appeal against EPO decision in favor of Cantargia patent

    Cantargia AB today reported that a third party has filed a Notice of Appeal after their previous unsuccessful attempt to challenge the validity of one of Cantargia's European patents. The appeal concerns the decision by the Opposition Division of the European Patent Office (EPO) to reject the opposition of Cantargia's patent, EP 3020730, for treatment of solid tumors by IL1RAP-targeting antibody. This patent is part of Cantargia's robust IP portfolio and as it is based on a divisional applicatio

  • PR Newswire

    Cantargia reports treatment of first triple negative breast cancer patient in TRIFOUR study

    Cantargia AB today reported treatment of the first triple negative breast cancer (TNBC) patient with nadunolimab and chemotherapy in the phase Ib/II clinical trial TRIFOUR. This trial, performed in collaboration with the Spanish Breast Cancer Group, GEICAM, will evaluate nadunolimab in combination with gemcitabine and carboplatin in up to 113 patients. Initially, the trial will focus on the safety of this combination and the first part is expected to be completed within 6-9 months.

  • PR Newswire

    Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision PromiseSM phase 2/3 clinical trial

    Cantargia AB today announced that the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM phase 2/3 clinical trial, carried out at leading clinical US centers, plans to include nadunolimab in combination with chemotherapy as first-line experimental therapy in metastatic pancreatic cancer (PDAC). The trial utilizes a Bayesian platform designed by PanCAN in collaboration with the US Food and Drug Administration (FDA) to provide a basis for marketing approval of therapies in PDAC. The p

Advertisement
Advertisement